Acurx Pharmaceuticals Net Income Over Time
| ACXP Stock | USD 2.14 0.05 2.28% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Acurx Pharmaceuticals Performance and Acurx Pharmaceuticals Correlation. Can Biotechnology industry sustain growth momentum? Does Acurx have expansion opportunities? Factors like these will boost the valuation of Acurx Pharmaceuticals. If investors know Acurx will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Acurx Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of Acurx Pharmaceuticals LLC is measured differently than its book value, which is the value of Acurx that is recorded on the company's balance sheet. Investors also form their own opinion of Acurx Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Acurx Pharmaceuticals' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Acurx Pharmaceuticals' market value can be influenced by many factors that don't directly affect Acurx Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Acurx Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Acurx Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Acurx Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Acurx Pharmaceuticals LLC and related stocks such as Aprea Therapeutics, Adial Pharmaceuticals, and Biocardia Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APRE | (3.5 M) | (254 K) | (254 K) | (436.2 K) | (15.2 M) | (15.2 M) | (15.2 M) | (15.2 M) | (15.5 M) | (28.1 M) | (53.9 M) | (36.5 M) | (112.7 M) | (14.3 M) | (13 M) | (11.7 M) | (12.2 M) |
| ADIL | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (420.2 K) | (1.1 M) | (11.6 M) | (8.6 M) | (10.9 M) | (19.4 M) | (12.7 M) | (7 M) | (13.2 M) | (11.9 M) | (12.5 M) |
| BCDA | 135.6 K | 9.7 M | 305 K | 19 K | 234 K | 322 K | (10.3 M) | (12.3 M) | (14 M) | (14.7 M) | (15 M) | (12.6 M) | (11.9 M) | (11.6 M) | (7.9 M) | (7.2 M) | (6.8 M) |
| HCWB | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (5.8 M) | (12.9 M) | (14.9 M) | (25 M) | (30 M) | (27 M) | (25.7 M) |
| GLTO | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (38.4 M) | (34.8 M) | (51.8 M) | (61.6 M) | (38.3 M) | (21.4 M) | (19.3 M) | (20.3 M) |
| CELZ | 1.4 K | (24.1 K) | (25.6 K) | (27.3 K) | (28 K) | (30.8 K) | (766.1 K) | (2.7 M) | (13.7 M) | (8.5 M) | (36.3 M) | 19.2 M | (10.1 M) | (5.3 M) | (5.5 M) | (4.9 M) | (5.2 M) |
| KPRX | (6 M) | (6 M) | (6 M) | (3.9 M) | (1.8 M) | (8.4 M) | (13.3 M) | (13.2 M) | (10.8 M) | (7.1 M) | (6.9 M) | (13.8 M) | (13.6 M) | (12.5 M) | 3.6 M | 3.2 M | 3.4 M |
| INAB | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (5.1 M) | (8.6 M) | (14.7 M) | (27.4 M) | (30 M) | (30.4 M) | (27.4 M) | (26 M) |
| APVO | (53.3 M) | (53.3 M) | (53.3 M) | (53.3 M) | (51.1 M) | (59.3 M) | (112.4 M) | 7 M | (53.7 M) | (44.7 M) | (17.8 M) | (27.3 M) | 8 M | (17.4 M) | (24.1 M) | (27.7 M) | (29.1 M) |
| BCLI | (25.6 K) | (3.9 M) | (3.4 M) | (4.9 M) | (9.2 M) | (8.5 M) | (5 M) | (5 M) | (13.9 M) | (23.3 M) | (31.8 M) | (24.5 M) | (23.7 M) | (17.2 M) | 11.6 M | 10.5 M | 11 M |
Acurx Pharmaceuticals LLC and related stocks such as Aprea Therapeutics, Adial Pharmaceuticals, and Biocardia Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Acurx Pharmaceuticals LLC financial statement analysis. It represents the amount of money remaining after all of Acurx Pharmaceuticals LLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Acurx Pharmaceuticals LLC | ACXP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 259 Liberty Avenue, |
| Exchange | NASDAQ Exchange |
USD 2.14
Additional Tools for Acurx Stock Analysis
When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.